OBJECTIVE: This study was undertaken to evaluate the potential role of G-protein-coupled estrogen receptor in endometrial pathology associated with tamoxifen treatment of breast cancer patients. STUDY DESIGN: We investigated whether G-protein-coupled estrogen receptor plays a role in mediating proliferating effect of tamoxifen in endometrial carcinoma cells. These results were compared with the G-protein-coupled estrogen receptor expression pattern in endometrial tissue from a cohort of 95 breast cancer patients, who received tamoxifen or another adjuvant therapy. RESULTS: In vitro tamoxifen significantly stimulated the mitogen-activated protein kinase phosphorylation and cell proliferation of endometrial cell lines via G-protein-coupled estrogen receptor. In vivo, there was a significant correlation between G-protein-coupled estrogen receptor expression and the tamoxifen-induced endometrial pathology (P = .006). Moreover, G-protein-coupled estrogen receptor positivity was predictive of an earlier development of symptoms, such as bleeding or suspect endometrial thickness, induced by tamoxifen therapy (P = .019). CONCLUSION: G-protein-coupled estrogen receptor plays an important role in tamoxifen-induced endometrial abnormalities.
OBJECTIVE: This study was undertaken to evaluate the potential role of G-protein-coupled estrogen receptor in endometrial pathology associated with tamoxifen treatment of breast cancerpatients. STUDY DESIGN: We investigated whether G-protein-coupled estrogen receptor plays a role in mediating proliferating effect of tamoxifen in endometrial carcinoma cells. These results were compared with the G-protein-coupled estrogen receptor expression pattern in endometrial tissue from a cohort of 95 breast cancerpatients, who received tamoxifen or another adjuvant therapy. RESULTS: In vitro tamoxifen significantly stimulated the mitogen-activated protein kinase phosphorylation and cell proliferation of endometrial cell lines via G-protein-coupled estrogen receptor. In vivo, there was a significant correlation between G-protein-coupled estrogen receptor expression and the tamoxifen-induced endometrial pathology (P = .006). Moreover, G-protein-coupled estrogen receptor positivity was predictive of an earlier development of symptoms, such as bleeding or suspect endometrial thickness, induced by tamoxifen therapy (P = .019). CONCLUSION: G-protein-coupled estrogen receptor plays an important role in tamoxifen-induced endometrial abnormalities.
Authors: Yin-Yan He; Gui-Qiang Du; Bin Cai; Qin Yan; Long Zhou; Xiao-Yue Chen; Wen Lu; Yi-Xia Yang; Xiao-Ping Wan Journal: J Cancer Res Clin Oncol Date: 2012-01-24 Impact factor: 4.553
Authors: Tapan K Nayak; Chinnasamy Ramesh; Helen J Hathaway; Jeffrey P Norenberg; Jeffrey B Arterburn; Eric R Prossnitz Journal: Mol Cancer Res Date: 2014-07-16 Impact factor: 5.852
Authors: Andrei A Tica; Erica C Dun; Oana S Tica; Xin Gao; Jeffrey B Arterburn; G Cristina Brailoiu; Tudor I Oprea; Eugen Brailoiu Journal: Am J Physiol Cell Physiol Date: 2011-08-24 Impact factor: 4.249
Authors: Nicolas Samartzis; Eleftherios P Samartzis; Aurelia Noske; André Fedier; Konstantin J Dedes; Rosmarie Caduff; Daniel Fink; Patrick Imesch Journal: Reprod Biol Endocrinol Date: 2012-04-20 Impact factor: 5.211
Authors: Fen Li; Xuan Yu; Claudia K Szynkarski; Cong Meng; Beiyan Zhou; Rola Barhoumi; Richard E White; Cristine L Heaps; John N Stallone; Guichun Han Journal: PLoS One Date: 2013-06-19 Impact factor: 3.240